CTLA4Ig Inhibits humoral and cellular immune responses to concordant xenografts.
Ibrahim
S
S
Division of Transplant Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Xu
R
R
Burdick
J F
JF
Baldwin
W
W
Sanfilippo
F
F
Kittur
D S
DS
D000069594:Abatacept; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000494:pharmacology*; D001803:Blood Transfusion; D060908:CTLA-4 Antigen; D016027:Heart Transplantation / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D018796:Immunoconjugates; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D051379:Mice; D008815:Mice, Inbred Strains; D051381:Rats; D011919:Rats, Inbred Strains; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D014183:Transplantation, Heterologous / Q000276:immunology* / Q000473:pathology
D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; C556707:Ctla4 protein, mouse; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000069594:Abatacept